Milestone, at its founding, sought to create new chemical entities as analogs of known molecular classes with clinically validated mechanisms of action. Our goal remains to preserve the beneficial pharmacology of existing molecules while altering their pharmacokinetic profile with focused medicinal chemistry to produce drugs that are fast-acting and rapidly inactivated in the blood to minimize potential side effects.

As a result, we are developing etripamil, a novel non-dihydropyridine calcium channel blocker.

We are currently conducting a comprehensive development program for etripamil designed to explore the following clinical outcomes:

• Administration: Etripamil is designed to be self-administered by patients via a nasal spray device.
• Absorption: Etripamil is designed to be absorbed into the bloodstream in less than 10 minutes through the inner lining of the nose, which has many blood vessels to maximize absorption.
• Action: Etripamil is designed to act rapidly upon the desired organ. Its short duration of action has the potential to avoid or reduce long-term side effects that can occur with chronic drug therapy.

Currently, etripamil is in Phase 3 development for the acute treatment of PSVT and a Phase 2 proof-of-concept study for the acute treatment of AFib with rapid ventricular rate (RVR). We are also considering investigating etripamil for patients living with other episodic conditions.